Fig. 1
Oxaliplatin-resistant HCT116OxR and HT29OxR cells have undergone EMT and increased drug efflux. a Schematic model presenting the process to acquire oxaliplatin-resistant CRC cells. b CCK8 assay of parent and resistant cell lines followed by oxaliplatin treatment at indicated concentrations. c Flow cytometry for apoptosis assay of parental and resistance cells with oxaliplatin treatment (30 μM). d The morphology of HCT116, HCT116-OxR, HT29 and HT29OxR cells. Scale bars, 50 μm. e Migration and invasion ability of parental and resistance CRC cells were assessed by Transwell assay. f Motility ability of parental and resistance CRC cells were assessed by wound healing assays. g Western blot analysis of protein E-cadherin (E-cad), N-cadherin (N-cad), Vimentin (Vim) and Fibronectin (Fn) expression in parental and resistance CRC cells. h Accumulation of Pt in parental and resistance cells following exposure to 30 μM, 24 h oxaliplatin treatment. i Total Pt-DNA adduct levels in parental and resistance cells following exposure to 30 μM, 24 h oxaliplatin treatment. j The immunofluorescence analysis of nuclear foci for γ-H2AX expression induced by oxaliplatin in parent and resistant cells after 24 h` oxaliplatin exposure. Scale bars, 10 μm. Results are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001